Global Biotherapeutics Cell Line Development Market Insights, Forecast to 2029

Publication ID:

PB504230966

Publication Date:

May 29, 2023

Pages:

114

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Market Analysis and Insights: Global Biotherapeutics Cell Line Development Market
The global Biotherapeutics Cell Line Development market is projected to grow from US$ 58250 million in 2023 to US$ 75420 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.4% during the forecast period.
The US & Canada market for Biotherapeutics Cell Line Development is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Biotherapeutics Cell Line Development is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Biotherapeutics Cell Line Development is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Biotherapeutics Cell Line Development include Becton Dickinson & Company, Beckman Coulter, Boehringer Ingelheim Group, Catalent Inc., CMC Biologics A/S, Lonza Group Ltd., EMD Millipore, Partec (Sysmex Corporation) and ProBioGen AG, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Biotherapeutics Cell Line Development market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Biotherapeutics Cell Line Development, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biotherapeutics Cell Line Development, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biotherapeutics Cell Line Development revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Biotherapeutics Cell Line Development market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Biotherapeutics Cell Line Development revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Becton Dickinson & Company, Beckman Coulter, Boehringer Ingelheim Group, Catalent Inc., CMC Biologics A/S, Lonza Group Ltd., EMD Millipore, Partec (Sysmex Corporation) and ProBioGen AG, etc.
By Company
Becton Dickinson & Company
Beckman Coulter
Boehringer Ingelheim Group
Catalent Inc.
CMC Biologics A/S
Lonza Group Ltd.
EMD Millipore
Partec (Sysmex Corporation)
ProBioGen AG
Selexis SA
Sigma-Aldrich Co. LLC.
Sony Biotechnology Inc.
Thermo Fisher Scientific Inc.
Segment by Type
Transfection & Selection
Single Cell Cloning
Segment by Application
In-house
Outsource
Hybrid
Do-It-Yourself (DIY)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biotherapeutics Cell Line Development in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biotherapeutics Cell Line Development companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biotherapeutics Cell Line Development revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biotherapeutics Cell Line Development Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Transfection & Selection
1.2.3 Single Cell Cloning
1.3 Market by Application
1.3.1 Global Biotherapeutics Cell Line Development Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 In-house
1.3.3 Outsource
1.3.4 Hybrid
1.3.5 Do-It-Yourself (DIY)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biotherapeutics Cell Line Development Market Perspective (2018-2029)
2.2 Global Biotherapeutics Cell Line Development Growth Trends by Region
2.2.1 Biotherapeutics Cell Line Development Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biotherapeutics Cell Line Development Historic Market Size by Region (2018-2023)
2.2.3 Biotherapeutics Cell Line Development Forecasted Market Size by Region (2024-2029)
2.3 Biotherapeutics Cell Line Development Market Dynamics
2.3.1 Biotherapeutics Cell Line Development Industry Trends
2.3.2 Biotherapeutics Cell Line Development Market Drivers
2.3.3 Biotherapeutics Cell Line Development Market Challenges
2.3.4 Biotherapeutics Cell Line Development Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Biotherapeutics Cell Line Development by Players
3.1.1 Global Biotherapeutics Cell Line Development Revenue by Players (2018-2023)
3.1.2 Global Biotherapeutics Cell Line Development Revenue Market Share by Players (2018-2023)
3.2 Global Biotherapeutics Cell Line Development Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biotherapeutics Cell Line Development, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Biotherapeutics Cell Line Development Market Concentration Ratio
3.4.1 Global Biotherapeutics Cell Line Development Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biotherapeutics Cell Line Development Revenue in 2022
3.5 Global Key Players of Biotherapeutics Cell Line Development Head office and Area Served
3.6 Global Key Players of Biotherapeutics Cell Line Development, Product and Application
3.7 Global Key Players of Biotherapeutics Cell Line Development, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biotherapeutics Cell Line Development Breakdown Data by Type
4.1 Global Biotherapeutics Cell Line Development Historic Market Size by Type (2018-2023)
4.2 Global Biotherapeutics Cell Line Development Forecasted Market Size by Type (2024-2029)
5 Biotherapeutics Cell Line Development Breakdown Data by Application
5.1 Global Biotherapeutics Cell Line Development Historic Market Size by Application (2018-2023)
5.2 Global Biotherapeutics Cell Line Development Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biotherapeutics Cell Line Development Market Size (2018-2029)
6.2 North America Biotherapeutics Cell Line Development Market Size by Type
6.2.1 North America Biotherapeutics Cell Line Development Market Size by Type (2018-2023)
6.2.2 North America Biotherapeutics Cell Line Development Market Size by Type (2024-2029)
6.2.3 North America Biotherapeutics Cell Line Development Market Share by Type (2018-2029)
6.3 North America Biotherapeutics Cell Line Development Market Size by Application
6.3.1 North America Biotherapeutics Cell Line Development Market Size by Application (2018-2023)
6.3.2 North America Biotherapeutics Cell Line Development Market Size by Application (2024-2029)
6.3.3 North America Biotherapeutics Cell Line Development Market Share by Application (2018-2029)
6.4 North America Biotherapeutics Cell Line Development Market Size by Country
6.4.1 North America Biotherapeutics Cell Line Development Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Biotherapeutics Cell Line Development Market Size by Country (2018-2023)
6.4.3 North America Biotherapeutics Cell Line Development Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Biotherapeutics Cell Line Development Market Size (2018-2029)
7.2 Europe Biotherapeutics Cell Line Development Market Size by Type
7.2.1 Europe Biotherapeutics Cell Line Development Market Size by Type (2018-2023)
7.2.2 Europe Biotherapeutics Cell Line Development Market Size by Type (2024-2029)
7.2.3 Europe Biotherapeutics Cell Line Development Market Share by Type (2018-2029)
7.3 Europe Biotherapeutics Cell Line Development Market Size by Application
7.3.1 Europe Biotherapeutics Cell Line Development Market Size by Application (2018-2023)
7.3.2 Europe Biotherapeutics Cell Line Development Market Size by Application (2024-2029)
7.3.3 Europe Biotherapeutics Cell Line Development Market Share by Application (2018-2029)
7.4 Europe Biotherapeutics Cell Line Development Market Size by Country
7.4.1 Europe Biotherapeutics Cell Line Development Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Biotherapeutics Cell Line Development Market Size by Country (2018-2023)
7.4.3 Europe Biotherapeutics Cell Line Development Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Biotherapeutics Cell Line Development Market Size (2018-2029)
8.2 China Biotherapeutics Cell Line Development Market Size by Type
8.2.1 China Biotherapeutics Cell Line Development Market Size by Type (2018-2023)
8.2.2 China Biotherapeutics Cell Line Development Market Size by Type (2024-2029)
8.2.3 China Biotherapeutics Cell Line Development Market Share by Type (2018-2029)
8.3 China Biotherapeutics Cell Line Development Market Size by Application
8.3.1 China Biotherapeutics Cell Line Development Market Size by Application (2018-2023)
8.3.2 China Biotherapeutics Cell Line Development Market Size by Application (2024-2029)
8.3.3 China Biotherapeutics Cell Line Development Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Biotherapeutics Cell Line Development Market Size (2018-2029)
9.2 Asia Biotherapeutics Cell Line Development Market Size by Type
9.2.1 Asia Biotherapeutics Cell Line Development Market Size by Type (2018-2023)
9.2.2 Asia Biotherapeutics Cell Line Development Market Size by Type (2024-2029)
9.2.3 Asia Biotherapeutics Cell Line Development Market Share by Type (2018-2029)
9.3 Asia Biotherapeutics Cell Line Development Market Size by Application
9.3.1 Asia Biotherapeutics Cell Line Development Market Size by Application (2018-2023)
9.3.2 Asia Biotherapeutics Cell Line Development Market Size by Application (2024-2029)
9.3.3 Asia Biotherapeutics Cell Line Development Market Share by Application (2018-2029)
9.4 Asia Biotherapeutics Cell Line Development Market Size by Region
9.4.1 Asia Biotherapeutics Cell Line Development Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Biotherapeutics Cell Line Development Market Size by Region (2018-2023)
9.4.3 Asia Biotherapeutics Cell Line Development Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Type
10.2.1 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Application
10.3.1 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Country
10.4.1 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Biotherapeutics Cell Line Development Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Becton Dickinson & Company
11.1.1 Becton Dickinson & Company Company Details
11.1.2 Becton Dickinson & Company Business Overview
11.1.3 Becton Dickinson & Company Biotherapeutics Cell Line Development Introduction
11.1.4 Becton Dickinson & Company Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.1.5 Becton Dickinson & Company Recent Developments
11.2 Beckman Coulter
11.2.1 Beckman Coulter Company Details
11.2.2 Beckman Coulter Business Overview
11.2.3 Beckman Coulter Biotherapeutics Cell Line Development Introduction
11.2.4 Beckman Coulter Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.2.5 Beckman Coulter Recent Developments
11.3 Boehringer Ingelheim Group
11.3.1 Boehringer Ingelheim Group Company Details
11.3.2 Boehringer Ingelheim Group Business Overview
11.3.3 Boehringer Ingelheim Group Biotherapeutics Cell Line Development Introduction
11.3.4 Boehringer Ingelheim Group Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.3.5 Boehringer Ingelheim Group Recent Developments
11.4 Catalent Inc.
11.4.1 Catalent Inc. Company Details
11.4.2 Catalent Inc. Business Overview
11.4.3 Catalent Inc. Biotherapeutics Cell Line Development Introduction
11.4.4 Catalent Inc. Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.4.5 Catalent Inc. Recent Developments
11.5 CMC Biologics A/S
11.5.1 CMC Biologics A/S Company Details
11.5.2 CMC Biologics A/S Business Overview
11.5.3 CMC Biologics A/S Biotherapeutics Cell Line Development Introduction
11.5.4 CMC Biologics A/S Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.5.5 CMC Biologics A/S Recent Developments
11.6 Lonza Group Ltd.
11.6.1 Lonza Group Ltd. Company Details
11.6.2 Lonza Group Ltd. Business Overview
11.6.3 Lonza Group Ltd. Biotherapeutics Cell Line Development Introduction
11.6.4 Lonza Group Ltd. Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.6.5 Lonza Group Ltd. Recent Developments
11.7 EMD Millipore
11.7.1 EMD Millipore Company Details
11.7.2 EMD Millipore Business Overview
11.7.3 EMD Millipore Biotherapeutics Cell Line Development Introduction
11.7.4 EMD Millipore Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.7.5 EMD Millipore Recent Developments
11.8 Partec (Sysmex Corporation)
11.8.1 Partec (Sysmex Corporation) Company Details
11.8.2 Partec (Sysmex Corporation) Business Overview
11.8.3 Partec (Sysmex Corporation) Biotherapeutics Cell Line Development Introduction
11.8.4 Partec (Sysmex Corporation) Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.8.5 Partec (Sysmex Corporation) Recent Developments
11.9 ProBioGen AG
11.9.1 ProBioGen AG Company Details
11.9.2 ProBioGen AG Business Overview
11.9.3 ProBioGen AG Biotherapeutics Cell Line Development Introduction
11.9.4 ProBioGen AG Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.9.5 ProBioGen AG Recent Developments
11.10 Selexis SA
11.10.1 Selexis SA Company Details
11.10.2 Selexis SA Business Overview
11.10.3 Selexis SA Biotherapeutics Cell Line Development Introduction
11.10.4 Selexis SA Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.10.5 Selexis SA Recent Developments
11.11 Sigma-Aldrich Co. LLC.
11.11.1 Sigma-Aldrich Co. LLC. Company Details
11.11.2 Sigma-Aldrich Co. LLC. Business Overview
11.11.3 Sigma-Aldrich Co. LLC. Biotherapeutics Cell Line Development Introduction
11.11.4 Sigma-Aldrich Co. LLC. Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.11.5 Sigma-Aldrich Co. LLC. Recent Developments
11.12 Sony Biotechnology Inc.
11.12.1 Sony Biotechnology Inc. Company Details
11.12.2 Sony Biotechnology Inc. Business Overview
11.12.3 Sony Biotechnology Inc. Biotherapeutics Cell Line Development Introduction
11.12.4 Sony Biotechnology Inc. Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.12.5 Sony Biotechnology Inc. Recent Developments
11.13 Thermo Fisher Scientific Inc.
11.13.1 Thermo Fisher Scientific Inc. Company Details
11.13.2 Thermo Fisher Scientific Inc. Business Overview
11.13.3 Thermo Fisher Scientific Inc. Biotherapeutics Cell Line Development Introduction
11.13.4 Thermo Fisher Scientific Inc. Revenue in Biotherapeutics Cell Line Development Business (2018-2023)
11.13.5 Thermo Fisher Scientific Inc. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Becton Dickinson & Company
Beckman Coulter
Boehringer Ingelheim Group
Catalent Inc.
CMC Biologics A/S
Lonza Group Ltd.
EMD Millipore
Partec (Sysmex Corporation)
ProBioGen AG
Selexis SA
Sigma-Aldrich Co. LLC.
Sony Biotechnology Inc.
Thermo Fisher Scientific Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂